These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 22123065)

  • 1. Antibodies for biodefense.
    Froude JW; Stiles B; Pelat T; Thullier P
    MAbs; 2011; 3(6):517-27. PubMed ID: 22123065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Antibodies for Biodefense.
    Avril A
    Adv Exp Med Biol; 2017; 1053():173-205. PubMed ID: 29549640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistence of category A select agents in the environment.
    Sinclair R; Boone SA; Greenberg D; Keim P; Gerba CP
    Appl Environ Microbiol; 2008 Feb; 74(3):555-63. PubMed ID: 18065629
    [No Abstract]   [Full Text] [Related]  

  • 4. Pathogen-specific recombinant human polyclonal antibodies: biodefence applications.
    Bregenholt S; Haurum J
    Expert Opin Biol Ther; 2004 Mar; 4(3):387-96. PubMed ID: 15006732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Practical strategies against bioterrorism].
    Matsumoto T
    Nihon Rinsho; 2007 Dec; 65(12):2363-73. PubMed ID: 18069284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bacillus anthracis, Francisella tularensis and Yersinia pestis. The most important bacterial warfare agents - review.
    Pohanka M; Skládal P
    Folia Microbiol (Praha); 2009; 54(4):263-72. PubMed ID: 19826916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recognition and management of bioterrorism infections.
    O'Brien KK; Higdon ML; Halverson JJ
    Am Fam Physician; 2003 May; 67(9):1927-34. PubMed ID: 12751654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Bacteriophage T4 Nanoparticle-Based Dual Vaccine against Anthrax and Plague.
    Tao P; Mahalingam M; Zhu J; Moayeri M; Sha J; Lawrence WS; Leppla SH; Chopra AK; Rao VB
    mBio; 2018 Oct; 9(5):. PubMed ID: 30327445
    [No Abstract]   [Full Text] [Related]  

  • 9. Bioterrorism.
    Rathjen NA; Shahbodaghi SD
    Am Fam Physician; 2021 Oct; 104(4):376-385. PubMed ID: 34652097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous manifestations of category A bioweapons.
    Aquino LL; Wu JJ
    J Am Acad Dermatol; 2011 Dec; 65(6):1213.e1-1213.e15. PubMed ID: 21777993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The microbiology laboratory's role in response to bioterrorism.
    Robinson-Dunn B
    Arch Pathol Lab Med; 2002 Mar; 126(3):291-4. PubMed ID: 11860302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiology of Pathogens Listed as Potential Bioterrorism Agents, the Netherlands, 2009‒2019.
    Broertjes J; Franz E; Friesema IHM; Jansen HJ; Reubsaet FAG; Rutjes SA; Stijnis C; Voordouw BCG; de Vries MC; Notermans DW; Grobusch MP
    Emerg Infect Dis; 2023 Jul; 29(7):1-9. PubMed ID: 37347519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Being prepared: bioterrorism and mass prophylaxis: part II.
    Weant KA; Bailey AM; Fleishaker EL; Justice SB
    Adv Emerg Nurs J; 2014; 36(4):307-17; quiz 318-9. PubMed ID: 25356890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparing for biological threats: Addressing the needs of pregnant women.
    Watson AK; Ellington S; Nelson C; Treadwell T; Jamieson DJ; Meaney-Delman DM
    Birth Defects Res; 2017 Mar; 109(5):391-398. PubMed ID: 28398677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reevaluating limits of detection of 12 lateral flow immunoassays for the detection of Yersinia pestis, Francisella tularensis, and Bacillus anthracis spores using viable risk group-3 strains.
    Ziegler I; Vollmar P; Knüpfer M; Braun P; Stoecker K
    J Appl Microbiol; 2021 Apr; 130(4):1173-1180. PubMed ID: 32970936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Being prepared: bioterrorism and mass prophylaxis: part I.
    Weant KA; Bailey AM; Fleishaker EL; Justice SB
    Adv Emerg Nurs J; 2014; 36(3):226-38; quiz 239-40. PubMed ID: 25076398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral options for biodefense.
    Byrd CM; Grosenbach DW; Hruby DE
    Curr Opin Virol; 2013 Oct; 3(5):537-41. PubMed ID: 23773331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histopathology and immunohistochemistry in the diagnosis of bioterrorism agents.
    Guarner J; Zaki SR
    J Histochem Cytochem; 2006 Jan; 54(1):3-11. PubMed ID: 16148309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical aspects of bio-terrorism.
    Balali-Mood M; Moshiri M; Etemad L
    Toxicon; 2013 Jul; 69():131-42. PubMed ID: 23339855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccines, biological warfare, and bioterrorism.
    Polgreen PM; Helms C
    Prim Care; 2001 Dec; 28(4):807-21, vii. PubMed ID: 11739031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.